Glenmark Pharma's wait for licencing deal ends

The year-long wait for Glenmark Pharmaceuticals to cut a licencing deal is finally over. The company partners with Sanofi-Aventis to develop and commercialise Glenmark's novel molecules for pain treatment led by GRC 15300

Related Videos